β-blockers in heart failure - Are all created equal?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 5, 2013, Pages 204-205

  Brignardello Petersen, Romina ^a,b   Guyatt, Gordon H ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CHILE   (Chile)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; PLACEBO; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; DISEASE COURSE; EDITORIAL; HEALTH CARE SURVEY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PATIENT; DOSE RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HUMANS; META-ANALYSIS AS TOPIC; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84880112591     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1720     Document Type: Editorial

References (15)

1. DiNicolantonio JJ, Lavie CJ, Fares H, et al. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol. 2013; 111: 765-769.
2. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996; 94: 2817-2825.
3. Rössig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000; 36: 2081-2089.
4. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013; 346: f55.
5. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012; 3: 80-97.
6. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011; 14: 417-428.
7. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64: 401-406.
8. Cooper NJ, Sutton AJ, Morris D, et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009; 28: 1861-1881.
9. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003; 362: 7-13.
10. Bristow MR, Adams KF Jr, Bauman JL, et al. The COMET trial. Congest Heart Fail. 2005; 11: 39-47.
11. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-re-lease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000; 283: 1295-1302.
12. Wikstrand J, Hjalmarson A, Waagstein F, et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2002; 40: 491-498.
13. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000; 101: 378-384.
14. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342: 1441-1446.
15. Kerwin T, Chavarria N. Assessment of metoprolol tartrate dosage in the outpatient setting. Am J Health Syst Pharm. 2012; 69: 1622-1626.